



The global prevalence of sickle cell anemia (SCA) is high, 
with over 30 million people affected, and sub-Saharan Africa 
accounts for nearly 70% of the world’s 300,000 newborn 
babies affected by SCA annually.[1] In Nigeria, about 25% of 
adults have the sickle cell trait (SCT), while the homozygous 
state (SS) is found in about 3% of the population.[2]
SCA is an inherited autosomal recessive disorder of the 
beta-globin chain of hemoglobin (Hb), characterized by 
hemolytic anemia, episodes of vaso-occlusion, and increased 
susceptibility to infections and sometimes organ damage.[3] The 
disorder is caused by a mutation leading to the replacement 
of glutamic acid with valine at the sixth position of the 
beta-globin chain.[4] The abnormal physiochemical properties 
of the resultant sickle red cell are responsible for the clinical 
manifestations of the disease. The underlying pathology 
of most of these complications is the recurrent episodes of 
vaso-occlusion due to microthrombi formation resulting in 
organ ischemia.[5] Although the clinical manifestations of 
the disease are quite heterogeneous, periodic vaso-occlusive 
crises and chronic intravascular hemolysis are common in 
SCA patients.[6]
SCA is associated with a hypercoagulable state as a result 
of enhanced generation of thrombin, impaired anticoagulant 
activity, increased platelet activation, and abnormal activation 
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of the fibrinolytic system.[7] The enhanced thrombin generation 
and altered the fibrinolytic system lead to fibrinogen proteolysis 
and the generation of fibrin degradation products, one of 
which is plasma D-dimer. Some studies have demonstrated 
an elevation in plasma D-dimer and alteration in coagulation 
indices in SCA patients, especially in steady state.[8-11] Plasma 
D-dimer has also been reported to be correlated with many 
clinical outcomes in the disease.[12,13]
However, while a number of previous studies have evaluated 
plasma D-dimer levels in SCA patients, the results are 
contradictory and inconsistent, thus suggesting the possible 
involvement of multiple pathophysiological mechanisms.[12,14,15] 
In addition, there is a paucity of information on the plasma 
level of D-dimer in SCA patients in this environment. 
Furthermore, despite its reported utility in predicting future 
clinical outcomes, plasma D-dimer is not routinely assessed 
in SCA patients. The aim of the study was to determine the 
mean plasma levels of D-dimer and other coagulation indices 
in children with SCA in a steady state and compare with that 
of healthy HbAA genotype controls.
MateRIals and Methods
Study area
The study was carried out at the sickle cell clinic of the State 
Specialist Hospital Maiduguri, Borno State, North-East 
Nigeria. The clinic runs weekly, mainly on Tuesdays with an 
inflow of ten to twenty patients per visit.
Study population and design
This case–control study involves SCA children in steady state 
and healthy HbAA genotype controls. Steady state was defined 
as the absence of acute painful crisis or any changes due to 
therapy for at least four consecutive weeks after a previous 
painful crisis.[13] A simple random sampling technique using 
a random number table was used to recruit the patients and an 
equal number of age- and sex-matched healthy HbAA controls 
were recruited.
Inclusion criteria
Participants are known to be SCA patients based on Hb 
electrophoresis results showing SS, who:
i. Fall within the age range of 4–15 years
ii. Were in steady state
iii. Not on oral anticoagulant therapy.
Exclusion criteria
i. Those with other hemoglobinopathies (based on history 
and clinical examination)
ii. HIV-positive patients
iii. Patients known to be hepatitis B positive or those with 
chronic liver disease from any cause.
Sample size determination
The sample size for the study was determined using G*Power 
computer software version 3.1.9.4.[16] Mean ± standard 
deviation (SD) plasma D-dimer in HbSS patients in steady 
state and HbAA subjects of 51.72 ± 34.12 and 37.25 ± 34.85, 
respectively, from a previous study by Ekwere et al.[12] was 
used which gave an effect size (d) of 0.4196. Using this effect 
size, α level of significance of 0.05, and the statistical power 
of 0.8, we obtained a sample size of 78.
Ethical clearance
Ethical clearance was obtained from the Ethics and Research 
Committee of the State Specialist Hospital, Maiduguri, 
with reference number: SSH/GEN/641/VOL. 1. Since the 
participants were minors, written informed consent was 
obtained from their respective parents/guardians as appropriate.
Data collection
Interviewer-administered data capture form was used to obtain 
sociodemographic, anthropometric, and laboratory data of the 
participants.
Anthropometric data
Weight was measured using a bathroom weighing scale 
with barefoot and light clothes. Height was measured in 
centimeter which was converted to meter scale. The body 
mass index (BMI) was calculated from the weight and height 
obtained using a formula: BMI = weight in kg/height in M2.
Laboratory procedures
A total of 8 ml of venous blood was drawn using a vacuum 
container (vacutainer) needle and emptied into two separate 
containers: 4.5 ml into trisodium citrate containing 3.2% 
sodium citrate for coagulation assays and 3.5 ml into 
ethylenediaminetetraacetic acid for hematological analysis. 
D-dimer was determined using enzyme-linked immunosorbent 
assay fluorescence immune assay kit (Guangzhou Wondfo 
Biotech Co., Ltd., Guangzhou, China) according to the 
manufacturer’s instructions. The test is based on fluorescence 
immunoassay techniques of antigen-antibodies reaction. When 
the sample is added into the sample well of the test cartridge, 
the flourescence-labelled detector D-dimer antibodies on the 
sample pad bind to D-dimer antigens in the plasma and form 
immune complexes. These complexes are then detected by 
fluorescence immunoassay.
Prothrombin time (PT) and activated partial thromboplastin 
time (aPTT) were determined using HumaClot Junior, a 
semi-automated coagulation machine with reference number 
18,680 SN-HC-6281 (Human Gesellschaft für Biochemica 
und Diagnostica mbH Max-Planck-Ring; Wiesbaden, 
Germany) according to the manufacturer’s instructions using 
PT reagent (Chemelex, S. A. Barcelona, Spain).
Platelet count was determined by direct current impedance 
method with hydrodynamic focusing using Sysmex Automated 
Hematology Analyzer XN550 (Sysmex Middle East FZ-LLC, 
Dubai Healthcare City, Dubai, UAE) as described by Simmons 
et al.[17]
Data analysis
Data were analyzed using JMP statistical software 
version 11 (SAS Institute Inc., NC, USA). Independent t-test 
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was used to compare the mean values between the two groups, 
and Pearson’s correlation coefficient was used to determine 
the linear relationship between D-dimer and other coagulation 
indices among SCA patients. The results were presented as 
mean ± SD and P ≤ 0.05 was considered statistically significant.
Results
A total of 80 participants consisting of 40 SCA patients in a 
stable state and 40 healthy HbAA children were recruited. 
The mean age of the SCA patients and the healthy controls 
was 13.98 ± 6.71 and 13.85 ± 7.45 (t = 0.126, P = 0.9374), 
respectively.
The SCA patients had significantly higher plasma 
D-dimer (3.18 ± 2.72 vs. 0.29 ± 0.52, t = 6.59, P = 0.001) and 
platelet count (449.70 ± 162.87 vs. 302.58 ± 83.34, t = 5.08, 
P = 0.0001) compared to healthy controls, respectively. 
Similarly, the SCA patients had prolonged PT (20.48 ± 6.51 vs. 
13.89 ± 2.13, t = 6.08, P = 0.0001) and aPTT (40.91 ± 9.08 vs. 
32.63 ± 4.44, t = 5.28, P = 0.0001) compared to the healthy 
controls, respectively. The results of coagulation parameters 
of the subjects are shown in Table 1.
Using a reference value of plasma D-dimer of 0.4–0.5 mg/L, 
about 98% of the SCA patients had higher plasma D-dimer to 
the control’s 8% (χ2 = 65.66, P = 0.0001) [Table 2].
D-dimer did not correlate with any other coagulation index 
among SCA patients [Table 3].
dIscussIon
This study investigated plasma levels of D-dimer and other 
coagulation indices among children with SCA in a steady state. 
Coagulation profile including platelet count, PT, aPTT, and 
plasma D-dimer levels were assessed for both SCA patients 
and controls. We found a significantly higher mean platelet 
count among the SCA patients in steady state compared to 
the controls. Several studies have linked SCA with increased 
platelet activation.[13,18,19] The higher platelet count observed in 
the SCA patients is believed to be due to increased release of 
markers of platelet activation, associated functional asplenia, 
and failure or lack of splenic sequestration of platelets.[7,20,21]
Our study demonstrated longer PT and aPPT among SCA 
patients compared to the controls. This is similar to what was 
reported by Chinawa et al.[22] among SCA patients in Nigeria. 
The prolongation in PT and aPTT in SCA patients observed 
in this study could be due to elevated platelet and thrombin 
levels, which activate the intrinsic clotting pathway even under 
normal conditions, thus leading to consumption of a number of 
clotting factors.[7] Liver injury and Vitamin K deficiency could 
also impair the former’s ability to synthesize and release new 
clotting factors as rapidly as they are consumed, thus leading to 
relative deficiency.[23,24] Indeed, PT tests the integrity of Vitamin 
K-dependent factors such as II, V, VII, and X, while aPTT tests 
that of factors such as VIII, IX, and XI.[25] Most of these factors 
play significant roles in the intrinsic coagulation pathway.
The mean D-dimer level in the SCA patients in steady state was 
found to be significantly higher compared to the controls. This 
indicates a hyperactive coagulation system with activation of 
fibrinolytic activity leading to generation of fibrin degradation 
products like D-dimer. Various studies involving SCA in 
steady state have reported higher plasma D-dimer levels.[13,26,27] 
However, Philips et al.[28] have documented lower plasma 
D-dimer levels, while Ekwere et al.[12] found no significant 
difference in the mean plasma D-dimer values of SCA patients 
compared to healthy controls. The differences observed 
between our results and others may be due to differences in 
research methodologies and the sample size employed. We 
found no correlation between D-dimer and other coagulation 
indices among SCA patients.
Patients with SCA exhibit increased plasma levels of 
prothrombin fragment and thrombin–antithrombin complexes, 
which are markers of thrombin generation.[7] Plasma from 
patients with sickle cell disease exhibits higher thrombin 
peak height, thrombin generation rates, and endogenous 
thrombin potential compared to age-matched controls.[29,30] 
Recent studies have suggested that the increased thrombin 
generation observed in SCA not only leads to thrombotic 
complications but also contributes to vascular inflammation 
and multiple organ damage in mouse models of the disease.[20,31] 
Indeed, it has been reported that red blood cell-mediated 
Table 2: Association between plasma D-dimer values and 
sickle cell status
Variable HbSS, n (%) HbAA, n (%) χ2 P
Normal 1 (2.5) 37 (92.5) 65.66 0.0001
High 39 (97.5) 3 (7.5)
Hb: Hemoglobin
Table 3: Correlation between D-dimer and other 






PT: Prothrombin time, aPTT: Activated partial prothrombin time
Table 1: Mean coagulation parameters of the participants




PT (s) 20.48±6.51 13.89±2.13 6.08 0.0001*
aPTT (s) 40.91±9.08 32.63±4.44 5.28 0.001*
Platelet 
(×109/mL)
449.70±162.87 302.58±83.34 5.08 0.0001*
D-dimer 
(mg/L)
3.18±2.72 0.29±0.52 6.59 0.0001*
*Statistically significant variable. Statistically significant variable, 
PT: Prothrombin time, aPTT: Activated partial prothrombin time, SD: 
Standard deviation, Hb: Hemoglobin
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coagulation hyperactivation and endothelial dysfunction leads 
to inflammation, vascular leakage, and thrombosis.[32-35]
Limitations
Our study is limited by our inability to assess other coagulation 
indices such as fibrinogen, Proteins C and S, and specific 
factors. We were also unable to assess other fibrin degradation 
products. Despite this shortcoming, we believe that the 
coagulation indices assessed in the study can give a good 
reflection of coagulation activity.
conclusIon
The SCA patients had significantly higher plasma D-dimer and 
platelet count and longer PT and aPTT compared to controls. 
There was no significant relationship between plasma D-dimer 
and other coagulation indices among the SCA patients.
Acknowledgment
The authors wish to thank the management and staff of State 
Specialist Hospital, Maiduguri, Borno State, for their support 
throughout this work.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
RefeRences
1. Akodu S, Diaku-Akinwumi I, Njokanma O. Age at diagnosis of 
sickle cell anaemia in lagos, Nigeria. Mediterr J Hematol Infect Dis 
2013;5:e2013001.
2. Akinyanju O. Guest editorial: Issues in management and control of 
sickle cells disorder. Achiev Ib Med 2001;2:37-41.
3. Mohamed AO, Nawal EO, Maria MH. Correlation between the plasma 
level of von willebrand factor and the severity of sickle cell disease in 
Sudanese patients. FASEB J 2007;21:A671.
4. Emechebe GO, Onyire NB, Orji ML, Archigbu KI. Sickle cell disease in 
Nigeria: A review. IOSR JDMS 2017;16:87-94.
5. Robbin K, Cotran M. Von Willebrand facto. In: Robbin K, Cotran M, 
editors. Text Book of Basic Pathology. 6th ed.. Philadelphia: Elsvier 
Saunders; 2005. p. 159-65.
6. Zhou Z. Haemoglobin blocks von willebrand factor proteolysis by 
ADAMTS-13: A mechanism associated with sickle cells disease. 
Thromb Haemost 2009;9:1070-7.
7. Ataga KI, Key NS. Hypercoagulability in sickle cell disease: New 
approaches to an old problem. Hematology Am Soc Hematol Educ 
Program 2007;2007:1:91-6.
8. Furie B, Furie BC. The molecular basis of blood coagulation. Cell 
1988;53:505-18.
9. Nsiri B, Gritli N, Mazigh C, Ghazouani E, Fattoum S, Machghoul S. 
Fibrinolytic response to venous occlusion in patients with homozygous 
sickle cell disease. Hematol Cell Ther 1997;39:229-32.
10. Hagger D, Wolff S, Owen J, Samson D. Changes in coagulation and 
fibrinolysis in patients with sickle cell disease compared with healthy 
black controls. Blood Coagul Fibrinolysis 1995;6:93-9.
11. Nsiri B, Gritli N, Bayoudh F, Messaoud T, Fattoum S, Machghoul S. 
Abnormalities of coagulation and fibrinolysis in homozygous sickle cell 
disease. Hematol Cell Ther 1996;38:279-84.
12. Ekwere T, Ogunro SP, Akanmu AS. Assessment of some fibrinolytic 
proteins in sickle cell anemia patients in steady state and in 
vaso-occlusive crises. J Appl Hematol 2013;4:131-6.
13. Kusfa IU, Mamman AI, Babadoko AA, Yahaya G, Ibrahim IN, 
Awwalu S, et al. A comparative study of D-dimer levels in adult patients 
with sickle cell anemia at Ahmadu Bello University Teaching Hospital 
Zaria, Nigeria. Blood 2017;14:92-5.
14. Famodu AA, Reid HL. Plasma fibrinogen levels in sickle cell disease. 
Trop Geogr Med 1987;39:36-8.
15. Buseri FI, Shokunbi WA, Jeremiah ZA. Plasma fibrinogen levels 
in Nigerian homozygous (Hb SS) sickle cell patients. Hemoglobin 
2007;31:89-92.
16. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses 
using G*Power 3.1: Tests for correlation and regression analyses. Behav 
Res Methods 2009;41:1149-60.
17. Simmons A, Schwabbauer ML, Earhart CA. Automatic platelet counting 
with the autoanalyzer. J Lab Clin Med 1971;77:656-60.
18. Francis RB. Large-vessel occlusion in sickle cell disease: Pathogenesis, 
clinical consequences, and therapeutic implications. Med Hypotheses 
1991;35:88-95.
19. Kenny MW, George AJ, Stuart J. Platelet hyperactivity in sickle-cell 
disease: A consequence of hyposplenism. J Clin Pathol 1980;33:622-5.
20. Helms CC, Marvel M, Zhao W, Stahle M, Vest R, Kato GJ, et al. 
Mechanisms of hemolysis-associated platelet activation. J Thromb 
Haemost 2013;11:2148-54.
21. Solovey A, Gui L, Key NS, Hebbel RP. Tissue factor expression by 
endothelial cells in sickle cell anemia. J Clin Invest 1998;101:1899-904.
22. Chinawa JM, Emodi IJ, Ikefuna AN, Ocheni S. Coagulation profile of 
children with sickle cell anemia in steady state and crisis attending the 
University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu. Niger J 
Clin Pract 2013;16:159-63.
23. Mills LR, Mwakyusa D, Milner PF. Histopathologic features of 
liver biopsy specimens in sickle cell disease. Arch Pathol Lab Med 
1988;112:290-4.
24. Charlotte F, Bachir D, Nénert M, Mavier P, Galactéros F, 
Dhumeaux D, et al. Vascular lesions of the liver in sickle cell disease. 
A clinicopathological study in 26 living patients. Arch Pathol Lab Med 
1995;119:46-52.
25. Katz D, Beilin Y. Disorders of coagulation in pregnancy. Br J Anaesth 
2015;115:75-88.
26. Francis RB Jr. Elevated fibrin D-dimer fragment in sickle cell anemia: 
Evidence for activation of coagulation during the steady state as well as 
in painful crisis. Haemostasis 1989;19:105-11.
27. Fakunle EE, Eteng KI, Shokunbi WA. D-dimer levels in patients with 
sickle cell disease during bone pain crises and in the steady state. Pathol 
Lab Med Int 2012;4:1-5.
28. Philips G, Hartman J, Keller VA, Santiago MA, Pizzo S. Regulation 
of tissue plasminogen activator in sickle cell anemia. Am J Hematol 
1990;35:167-70.
29. Noubouossie DF, Lê PQ, Corazza F, Debaugnies F, Rozen L, Ferster A, 
et al. Thrombin generation reveals high procoagulant potential in the 
plasma of sickle cell disease children. Am J Hematol 2012;87:145-9.
30. Noubouossie DC, Le PQ, Rozen L, Debaugnies F, Ferster A, 
Demulder A. Evaluation of the procoagulant activity of endogenous 
phospholipids in the platelet-free plasma of children with sickle cell 
disease using functional assays. Thromb Res 2012;130:259-64.
31. Sparkenbaugh EM, Chantrathammachart P, Mickelson J, van Ryn J, 
Hebbel RP, Monroe DM, et al. Differential contribution of FXa and 
thrombin to vascular inflammation in a mouse model of sickle cell 
disease. Blood 2014;123:1747-56.
32. Platt OS. Sickle cell anemia as an inflammatory disease. J Clin Invest 
2000;106:337-8.
33. Arumugam PI, Mullins ES, Shanmukhappa SK, Monia BP, Loberg A, 
Shaw MA, et al. Genetic diminution of circulating prothrombin 
ameliorates multiorgan pathologies in sickle cell disease mice. Blood 
2015;126:1844-55.
34. Sparkenbaugh E, Pawlinski R. Interplay between coagulation 
and vascular inflammation in sickle cell disease. Br J Haematol 
2013;162:3-14.
35. Zhang D, Xu C, Manwani D, Frenette PS. Neutrophils, platelets, 
and inflammatory pathways at the nexus of sickle cell disease 
pathophysiology. Blood 2016;127:801-9.
Nigerian Journal of Medicine ¦ Volume 29 ¦ Issue 4 ¦ October-December 2020 637
